Acadia Healthcare Company, Inc.
ACHCAcadia Healthcare Company, Inc. is an American provider of for-profit behavioral healthcare services. It operates a network of over 225 facilities across the United States and Puerto Rico. The company is headquartered in Franklin, Tennessee. As of 2024, Acadia operated over 50 inpatient psychiatric hospitals in 19 U.S. states, including Arizona, Arkansas, Florida, Georgia, Indiana, Michigan, Missouri, New Mexico, Ohio, Oklahoma, Pennsylvania, Tennessee, Utah, and Wisconsin. It is one of the country's largest hospital systems. It also operates, as of 2024, 165 methadone clinics in 33 states, making it the U.S.'s largest methadone-clinic chain.
Drugs in Pipeline
6
Phase 3 Programs
4
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Pimavanserin
Neuropsychiatric Symptoms Related to Neurodegenerative Disease
ACP-204
Alzheimer's Disease Psychosis
Trofinetide
Rett Syndrome
pimavanserin tartrate (ACP-103)
Parkinson's Disease Psychosis
Pimavanserin tartrate
Alzheimer's Disease Psychosis
ACP-103
Schizophrenia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Pimavanserin | Phase 3 | Neuropsychiatric Symptoms Related to Neurodegenerative Disease | - | - |
ACP-204 | Phase 3 | Alzheimer's Disease Psychosis | - | - |
Trofinetide | Phase 3 | Rett Syndrome | - | - |
pimavanserin tartrate (ACP-103) | Phase 3 | Parkinson's Disease Psychosis | - | - |
Pimavanserin tartrate | Phase 2 | Alzheimer's Disease Psychosis | - | - |
ACP-103 | Phase 2 | Schizophrenia | - | - |